Member Companies


About BiomeSense
BiomeSense is revolutionizing human microbiome research by creating novel tools to track, analyze, and store daily microbiome profiles of clinical trial participants, providing vastly more data than is possible with current tools, all for a fraction of the cost. This gives investigators far deeper insight into how the microbiome influences and is influenced by clinical interventions.

Kevin Honaker – Co-Founder & Chief Executive Officer
Dr. Jack Gilbert – Co-Founder
Dylan Nichols – Chief Technology Officer
Dr. Savas Tay – Scientific Advisor & Co-Founder

Twitter: @BiomeSense

Freya Biosciences

About Freya Biosciences

Freya™ is a clinical-stage biotech company taking an innovative approach to women’s health, with microbial immunotherapies aimed at relieving the chronic inflammation underlying a range of reproductive system diseases uniquely afflicting women. Freya’s drug candidates comprise full-spectrum microbiota and rationally-selected strain consortia, which have the potential to restore an optimal, non-inflammatory vaginal microbiome. Freya has completed two proof-of-concept studies, as well as a prospective cohort study in IVF, expanding biomarker data in the initial target population, and feeding into the company’s multi-omics data platform. Freya’s next generation therapeutics are currently in development and will be tested in clinical trials in the near future. Freya was established in 2020 and has headquarters in Copenhagen, Denmark and Boston, Massachusetts.

Colleen Acosta, PhD – Founder and Chief Executive Officer
Johan van Hylckama Vlieg, PhD – Founder and Chief Scientific Officer
Ulrich Binné, PhD JD – Founder and Chief Business Officer
Joan-Carles Arce, MD PhD – Chief Medical Officer
Crilles Casper Larsen, PhD Pharm – Senior Vice President CMC and Quality


Genetic Analysis

About Genetic Analysis

Genetic Analysis (GA) is a molecular diagnostic company with core focus within microbiome and has developed and launched the GA-map® Platform for gut microbiome analysis. The first marker is the GA-map Dysbiosis Test, the first documented CE marked routine test to identify and characterize the gut microbiota composition, initially targeted at IBS and IBD patients.
The results are immediately compared to a clinical validated normal healthy population through the advanced GA-map® software algorithm. This enables immediate results without any further bioinformatics work needed. GA-map® is currently the only routine diagnostic tool for microbiota.

Commercialisation has started on the European and US market and the GA-map® Test platform will increase the efficiency in the Lab and provide customers with superb quality results that is unique within the microbiome diagnostics area.

GA collaborates with pharma companies and academia in research projects for product documentation, new marker discovery and clinical research.

GA has new biomarker development projects ongoing in order to utilize the platform for other disease areas and has a unique bio-Bank with more than 7000 samples within different cohorts i.e; Healthy normals, IBD, Cdiff, IBS, Diabetes T2, RA, Parkinson.

Ronny Hermansen, CEO
Christina Casén, Director of Clinical and Medical Affairs
Finn Terie Hegge, CTO, Head of Operations

Twitter: @GeneticAnalysis

Rebiotix Inc.

About Rebiotix

Rebiotix Inc, which is part of the Ferring Pharmaceuticals Group, is a late-stage clinical microbiome company focused on harnessing the power of the human microbiome to revolutionize the treatment of debilitating diseases. Rebiotix possesses a deep and diverse clinical pipeline, with its lead drug candidate, RBX2660, in Phase 3 clinical development for the prevention of recurrent Clostridium difficile (C. diff) infection. RBX2660 has been granted Fast Track status, Orphan Drug and Breakthrough Therapy designation from the FDA for its potential to prevent recurrent C. diff infection. Rebiotix’s clinical pipeline also features RBX7455, a lyophilized non-frozen, oral capsule formulation, which is currently moving into a Phase 2 IND trial for the prevention of recurrent C. diff infection having completed an investigator sponsored Phase 1 study. In addition, Rebiotix is targeting several other disease states with drug products built on its pioneering Microbiota Restoration Therapy™ platform. The MRT™ platform is a standardized, stabilized drug technology that is designed to rehabilitate the human microbiome by delivering a broad consortium of live microbes into a patient’s intestinal tract via a ready-to-use and easy-to-administer format.

Target Indications
Recurrent C. diff prevention
VRE Elimination
Pediatric Ulcerative Colitis
Multi-drug Resistant UTI
Hepatic Encephalopathy

Lee Jones – Founder, President, and Chief Executive Officer
Dale N. Gerding, M.D., MACP, FIDSA, FSHEA – Chief Medical Officer
Ken F. Blount, Ph.D. – Chief Scientific Officer
Edward S. Burd, Ph.D. – Head of Regulatory Affairs
Nancy Timm, VP of Finance and Operations

Twitter: @Rebiotix

Seres Therapeutics

About Seres

Seres Therapeutics, Inc. (Nasdaq: MCRB) is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced. Seres’ SER-287 program has obtained Fast Track and Orphan Drug designation from the U.S. Food and Drug Administration and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres’ SER-109 program has obtained Breakthrough Therapy and Orphan Drug designations from the FDA and is in Phase 3 development for recurrent C. difficile infection. Seres is also developing SER-401 in a Phase 1b study in patients with metastatic melanoma.

Target Indications
C. difficile
Ulcerative Colitis
Inflammatory bowel disease

Eric Shaff – President, Chief Executive Officer
John Aunins, Ph.D. – Executive Vice President, Bioprocess & Manufacturing and Chief Technology Officer
Thomas J. DesRosier, Esq. – Executive Vice President, Chief Legal Officer and Secretary
Matthew Henn, Ph.D. – Executive Vice President, Chief Scientific Officer
Lisa von Moltke, M.D. – Executive Vice President, Chief Medical Officer
Jim Weston – Senior Vice President, Regulatory Affairs

Twitter: @SeresTX

Siolta Therapeutics

About Siolta

Siolta Therapeutics is a clinical-stage biotech company on a mission to alleviate the suffering of millions impacted by chronic inflammatory diseases through novel microbiome-based medicines. Siolta leverages its deep knowledge of the developing infant gut microbiome and its role in promoting immune tolerance to develop targeted microbial therapeutics and companion diagnostics for the prevention and treatment of inflammatory diseases. The company’s blended expertise from microbiology, immunology, and bioinformatics supports the development of a multifaceted platform, integrating ecosystems approaches and precision medicine concepts to advance the future of medicine. Currently focused on the clinical development of their lead product for the prevention and treatment of allergic asthma, Siolta’s holistic, microbiome-based strategy represents a new frontier in the pursuit of tailored, clinically differentiated microbial therapeutics.

Target Indications
Allergic Asthma
Food Allergy
Atopic Dermatitis
Allergic Rhinitis
Prevention of Allergic Disease
Metabolic Disease
Post-Antibiotic Recovery

Nikole Kimes, Ph.D. – Founder, Chief Executive Officer
Richard Shames, M.D. – Consulting CMO
Ricardo Valladares, Ph.D. – Vice President of Research and Development
Susan Lynch, Ph.D. – Founder, Member of the Board of Directors
Samir Kaul, MBA – Member of the Board of Directors

Twitter: @SioltaThera

Vedanta Biosciences

About Vedanta

Vedanta Biosciences is developing a new category of therapies for immune-mediated and infectious diseases based on rationally defined consortia of human microbiome-derived bacteria. Vedanta Biosciences is a leader in the microbiome field with capabilities and deep expertise to discover, develop, and manufacture live bacteria drugs. These include what is believed to be the largest collection of human microbiome-associated bacterial strains, a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing of rationally-defined bacterial consortia in powder form.

Vedanta Biosciences’ pioneering work, in collaboration with its scientific co-founders, has led to the identification of human commensal bacteria that induce a range of immune responses – including induction of regulatory T cells, CD8+ T cells, and Th17 cells, among others. These advances have been published in leading peer-reviewed journals including Science (multiple), Nature (multiple), Cell and Nature ImmunologyVedanta Biosciences has harnessed these biological insights and its capabilities to generate a pipeline of programs in infectious disease, autoimmune disease, allergy, and immune-oncology.

Target Indications
C. difficile
Inflammatory Bowel Disease
Food Allergy
Multi-drug Resistant Organisms
Cancer Immunotherapy

Bernat Olle, Ph.D. – Chief Executive Officer
Dan Couto – Chief Operations Officer
Jeffrey Silber, M.D. – Chief Medical Officer
Anne Kuan – SVP, Regulatory Affairs

Twitter: @VedantaBio

Microba Life Sciences

About Microba Life Sciences

Microba Life Sciences is a pre-clinical precision microbiome science company taking a human-first, data-driven approach to therapeutic discovery. Powered by precision analysis, Microba’s therapeutic discovery platform uses human data and leading informatic approaches to connect microbial genotype to human phenotype. Pioneered by our founders, our unique approach to culturing novel bacteria through genome-directed isolation provides us with novel disease-relevant bacterial isolates. The lead candidates derived from the human first, data driven approach have achieved excellent results and are being prepared for human trials.

Target Indications
Inflammatory Bowel Disease
Cancer – Immune Checkpoint Inhibitor Adjuvant Therapy

Professor Ian Frazer AC, Chair of Medical Advisory Board
Professor Gene Tyson, Chief Scientist, Co-Founder
Professor Phil Hugenholtz, Chief Scientist, Co-Founder
Blake Wills, Chief Executive Officer
Dr Luke Holtham Reid, President
Associate Professor Lutz Krause, Head of Data-mining and Artificial Intelligence
Dr Páraic Ó Cuív, Lead Live Biotherapeutics
Associate Professor Jake Begun, Medical Advisory Board, IBD Advisory Panel

Twitter: @microbaofficial

Alveolus Bio

About Alveolus Bio

Alveolus Bio is developing safe, targeted, and efficacious therapies for lung diseases. Founded and managed by physician scientists based on 15+ years of research into neutrophilic inflammation and microbial dysbiosis associated with chronic pulmonary disease, Alveolus Bio is focused on lung diseases of infancy, childhood, and adulthood. Specifically, Alveolus Bio’s drug development pipeline includes breakthrough therapeutics for respiratory indications such as Chronic Obstructive Pulmonary Disease (COPD), Bronchopulmonary Dysplasia (BPD), and Idiopathic Pulmonary Fibrosis (IPF), as well as a discovery program for Pulmonary Arterial Hypertension (PAH). The founders have assembled a team of leading researchers in the fields of respiratory medicine, microbiome science, and drug delivery modalities to pioneer novel biotherapeutics and delivery models.

Target Indications
Chronic Obstructive Pulmonary Disease (COPD)
Bronchopulmonary Dysplasia (BPD)
Idiopathic Pulmonary Fibrosis (IPF)
Pulmonary Arterial Hypertension (PAH)

C Vivek Lal MD FAAP, Founder and CEO


MaaT Pharma

About MaaT Pharma
MaaT Pharma is a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer. Listed on Euronext Paris (ticker: MAAT), MaaT Pharma is revolutionizing cancer treatment and currently has two drug candidates in clinical development. MaaT013, the Company’s lead asset, is currently being evaluated in Phase 3 clinical trial in the treatment of aGvHD (Acute Graft-versus-Host Disease), in Europe, marking the first Phase 3 study of a microbiome therapy in hemato-oncology worldwide. Additionally, the Company is also evaluating MaaT013 in a Phase 2 Proof of Concept study to enhance responses to immunotherapy, in metastatic melanoma. The Company’s second asset is MaaT033, an oral formulation designed for outpatients undergoing allo-HSCT and aimed to improve overall survival. Additionally, MaaT Pharma will be evaluating its potential in slowing ALS (Lou Gehrig’s disease) progression in a pilot Phase 1b study.

MaaT Pharma utilizes gutPrint®, a robust discovery and analysis platform, to identify disease targets, evaluate drug candidates, and uncover biomarkers for microbiome-related conditions. The company’s Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice. To support its development effort, the Company is currently building, in partnership with Skyepharma, the largest European cGMP manufacturing facility for clinical and commercial production entirely dedicated to microbiome-based therapy.

Hervé Affagard – CEO and Co-Founder
Philippe Moyen – Chief Operating Officer
Nathalie Corvaïa – Chief Scientific Officer
Siân Crouzet – Chief Financial Officer
Pr. Gervais Tougas – Chief Medical Officer
Carole Schwintner – Chief Technology Officer